Public Knowledge – Page 4

Patient-reported outcomes associated with reflex BRCA1/2 tumor and subsequent germline panel genetic testing for high-grade serous ovarian cancer.
McCuaig JM, Stockley TL, Ferguson SE, Vicus D, Brennenstuhl S, Ott K, Kim RH, Metcalfe KA.
J Genet Couns. 2022 Dec 7. doi: 10.1002/jgc4.1661. Epub ahead of print.

Clinical and psychological implications of secondary and incidental findings in cancer susceptibility genes after exome sequencing in patients with rare disorders.
Carrasco E, López-Fernández A, Codina-Sola M, Valenzuela I, Cueto-González AM, Villacampa G, Navarro V, Torres-Esquius S, Palau D, Cruellas M, Torres M, Perez-Dueñas B, Abulí A, Diez O, Sábado-Álvarez C, García-Arumí E, Tizzano EF, Moreno L, Balmaña J.
J Med Genet. 2022 Nov 29:jmg-2022-108929. doi: 10.1136/jmg-2022-108929. Epub ahead of print.

LitAlert ~~ GeneLit.com

BRCAShare-Assessment of an animated digital message for intrafamilial communication of pathogenic variant positive test results: A feasibility study.
Aeilts AM, Carpenter KM, Hovick SR, Byrne L, Shoben AB, Senter L.
J Genet Couns. 2022 Nov 25. doi: 10.1002/jgc4.1656. Epub ahead of print.

Testing a deliberative democracy method with citizens of African ancestry to weigh pros and cons of targeted screening for hereditary breast and ovarian cancer risk.
Guan Y, Pathak S, Ballard D, Veluswamy JK, McCullough LE, McBride CM, Gornick MC.
Front Public Health. 2022 Nov 8;10:984926. doi: 10.3389/fpubh.2022.984926.

Nest Genomics Building EHR-Integrated Clinical Decision Support for Genetics-Informed Care.
Cohen JK.
GenomeWeb. Disease Areas. Cancer. 2022 Oct 25.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer.
[No author given]
GenomeWeb. The Scan. 2022 Nov 23.

•• Original research:

A digital pathway for genetic testing in UK NHS patients with cancer: BRCA-DIRECT randomised study internal pilot.

Investigating Psychological Impact after Receiving Genetic Risk Results—A Survey of Participants in a Population Genomic Screening Program.
Zayac McCormick CZ, Dilzell Yu K, Johns A, Campbell-Salome G, Hallquist MLG, Sturm AC, Buchanan AH.
J Pers Med. 2022 Nov 22;12(12):1943. doi: 10.3390/jpm12121943.

Four-in-Five Eligible Breast Cancer Patients Not Informed of Genomic Testing Options.
[No author given]
Inside Precision Medicine. Topics. Oncology. 2022 Nov 21.

Fatalism and metaphor in Confucianism: A qualitative study of barriers to genetic testing among first-degree relatives of hereditary cancer patients from China.
Jiang C, Liu L, Wang Y, Wu L, Zhang W, Wu X.
Psychooncology. 2022 Nov 15. doi: 10.1002/pon.6068. Epub ahead of print.

Latinx attitudes, barriers, and experiences with genetic counseling and testing: A systematic review.
Dron HA, Bucio D, Young JL, Tabor HK, Cho MK.
J Genet Couns. 2022 Oct 27. doi: 10.1002/jgc4.1632. Epub ahead of print.

Genetic Testing Among Patients with High-Risk Breast, Ovarian, Pancreatic, and Prostate Cancers.
Clark NM, Roberts EA, Fedorenko C, Sun Q, Dubard-Gault M, Handford C, Yung R, Cheng HH, Sham JG, Norquist BM, Flanagan MR.
Ann Surg Oncol. 2022 Nov 5. doi: 10.1245/s10434-022-12755-y. Epub ahead of print.

Development of a web-based, theory-guided narrative intervention for women at elevated risk for breast cancer.
Katz ML, Senter L, Reiter PL, Emerson B, Ennis AC, Shane-Carson KP, Aeilts A, Cassingham HR, Schnell PM, Agnese DM, Toland AE, Sweet K.
Patient Educ Couns. 2022 Oct 29:S0738-3991(22)00820-5. doi: 10.1016/j.pec.2022.10.348. Epub ahead of print.

What happens in the long term: Uptake of cancer surveillance and prevention strategies among at-risk relatives with pathogenic variants detected via cascade testing.
Frey MK, Ahsan MD, Badiner N, Lin J, Narayan P, Nitecki R, Rauh-Hain JA, Moss H, Fowlkes RK, Thomas C, Bergeron H, Christos P, Levi SR, Blank SV, Holcomb K, Cantillo E, Sharaf RN, Lipkin S, Offit K, Chapman-Davis E.
Cancer. 2022 Oct 27. doi: 10.1002/cncr.34482. Epub ahead of print.